Simoa Cytokine Storm Profiling


Simoa Cytokine Storm Profiling

The use of Simoa™ technology to measure cytokines in both singleplex and multiplex configurations with excellent precision and limits of detection in the low fg/mL or sub–fg/mL levels, allowing robust quantification well below what is possible today.

Cytokines serve as critical modulators for the immune system. Maintaining the delicate balance in the level of these proteins is essential for overall health and immune response. As early signals of reaction to viral infection and acute immune response, measuring levels cytokines and chemokines in peripheral blood offer researchers and clinicians a means to monitor immune system dysfunction and progression to Cytokine Release Syndrome (CRS). New research is very quickly mounting around the risk of COVID-19 infection resulting in severe CRS otherwise known as Cytokine Storm.

Quanterix is enabling testing to:
  • Identify important ways to predict disease severity early on the disease course
  • Monitor progression and cytokine dysregulation
  • Quantify previously unmeasurable impact of drugs on disease progression

Simoa Cytokine Storm Profiling


Available biomarkers for studying Cytokine Storm

The Simoa technology is unique in its ability to simultaneously and precisely measure multiple cytokines down to baseline levels, enabling scientists to uncover a unique and comprehensive understanding of SARS-CoV-2 pathogenesis and host response.


Learn more by clicking the plus signs on the image below

Ready to take the next step in accessing a highly sensitive and accurate multiplex test to monitor the immune response to viral infection?
Email us!

Latest Publications

Samples require no pretreatment, no special handling and no molecular laboratory measures against carryover contamination associated with amplification methods.

Latest News

Ted Wayman reports on the recent $20 million contract awarded to Quanterix by the National Institutes of Health to see if their blood test for COVID-19 is more accurate than the current nasal swab test.
$18.2 million in Phase 2 funding will support the development and scale-up of COVID-19 antigen test based on Simoa® technology  

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more